Pipeline cell video thumbnail

Our Pipeline

We are developing an innovative cell therapy pipeline with the potential to redefine standards of care across a range of conditions where there is an urgent medical need. We are applying our proprietary CD34+ cell technology to potentially treat a number of conditions caused by underlying ischemic injury, including but not limited to, Coronary Microvascular Dysfunction (CMD), Critical Limb Ischemia (CLI), No-Option Refractory Disabling Angina (NORDA) and Diabetic Kidney Disease (DKD). These indications represent major areas of clinical need, as well as substantial commercial opportunities. Explore our pipeline below for information on our clinical development candidates and ongoing clinical trials.

ProgramClinical StatusPre ClinicalPhase 1Phase 2Phase 3Commercial

CLBS16

Coronary Microvascular Dysfunction

Freedom Phase 2B Trial (USA; Ongoing)

Pre Clinical
Phase 1
Phase 2
Phase 3
Commercial

HONEDRA® (CLBS12) SAKIGAKE DESIGNATED

Critical Limb Ischemia + Buerger’s Disease

Registration Eligible Trial (Japan; Ongoing)

Pre Clinical
Phase 1
Phase 2
Phase 3
Commercial

CLBS201

Diabetic Kidney Disease (DKD)
Clinical Status:

Phase 2 (USA; Clinical Initiation Pending)

Phase 2 (USA; Clinical Initiation Pending)

Pre Clinical
Phase 1
Phase 2
Phase 3
Commercial

CLBS14 (OLOGO™ in the U.S.) RMAT Designated

No-Option Refractory Disabling Angina
Clinical Status:

Phase 3 (USA; Initiation pending)

Phase 3 (USA; Initiation pending)

Pre Clinical
Phase 1
Phase 2
Phase 3
Commercial
* Products are distinct and not interchangeable.
* Timing subject to the COVID-19 pandemic influence.